These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 28477059)

  • 1. Change in carbohydrate antigen 19-9 level as a prognostic marker of overall survival in locally advanced pancreatic cancer treated with concurrent chemoradiotherapy.
    Kim YJ; Koh HK; Chie EK; Oh DY; Bang YJ; Nam EM; Kim K
    Int J Clin Oncol; 2017 Dec; 22(6):1069-1075. PubMed ID: 28477059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concurrent Chemoradiotherapy Versus Chemotherapy Alone for Unresectable Locally Advanced Pancreatic Cancer: A Retrospective Cohort Study.
    Choi Y; Oh DY; Kim K; Chie EK; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Ha SW; Bang YJ
    Cancer Res Treat; 2016 Jul; 48(3):1045-55. PubMed ID: 26511805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensity modulated radiotherapy for locally advanced and metastatic pancreatic cancer: a mono-institutional retrospective analysis.
    Wang Z; Ren ZG; Ma NY; Zhao JD; Zhang Z; Ma XJ; Long J; Xu J; Jiang GL
    Radiat Oncol; 2015 Jan; 10():14. PubMed ID: 25575617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of carbohydrate antigen 19-9 in unresectable locally advanced pancreatic cancer treated with dose-escalated intensity modulated radiation therapy and concurrent full-dose gemcitabine: analysis of a prospective phase 1/2 dose escalation study.
    Vainshtein JM; Schipper M; Zalupski MM; Lawrence TS; Abrams R; Francis IR; Khan G; Leslie W; Ben-Josef E
    Int J Radiat Oncol Biol Phys; 2013 May; 86(1):96-101. PubMed ID: 23265573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Consolidation Chemoradiotherapy in Locally Advanced Pancreatic Cancer Receiving Chemotherapy: An Updated Systematic Review and Meta-Analysis.
    Chang JS; Chiu YF; Yu JC; Chen LT; Ch'ang HJ
    Cancer Res Treat; 2018 Apr; 50(2):562-574. PubMed ID: 28602054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive Value of Serum Carbohydrate Antigen 19-9 (CA19-9) for Early Mortality in Advanced Pancreatic Cancer.
    Usón Junior PLS; Callegaro-Filho D; Bugano DDG; Moura F; Maluf FC
    J Gastrointest Cancer; 2018 Dec; 49(4):481-486. PubMed ID: 28924968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A nomogram for predicting survival of patients with locally advanced pancreatic cancer treated with chemoradiotherapy.
    Choi SH; Park SW; Seong J
    Radiother Oncol; 2018 Nov; 129(2):340-346. PubMed ID: 30177371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CA 19-9 as a predictor for response and survival in advanced pancreatic cancer patients treated with chemoradiotherapy.
    Koom WS; Seong J; Kim YB; Pyun HO; Song SY
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1148-54. PubMed ID: 18760544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Definitive concurrent chemoradiotherapy in locally advanced pancreatic cancer.
    Kwak YK; Lee JH; Lee MA; Chun HG; Kim DG; You YK; Hong TH; Jang HS
    Radiat Oncol J; 2014 Jun; 32(2):49-56. PubMed ID: 25061572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined detection of preoperative serum CEA, CA19-9 and CA242 improve prognostic prediction of surgically treated colorectal cancer patients.
    Wang J; Wang X; Yu F; Chen J; Zhao S; Zhang D; Yu Y; Liu X; Tang H; Peng Z
    Int J Clin Exp Pathol; 2015; 8(11):14853-63. PubMed ID: 26823815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma.
    Xu HX; Liu L; Xiang JF; Wang WQ; Qi ZH; Wu CT; Liu C; Long J; Xu J; Ni QX; Yu XJ
    Surgery; 2017 Feb; 161(2):373-384. PubMed ID: 27838102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concurrent chemoradiotherapy using proton beams for unresectable locally advanced pancreatic cancer.
    Hiroshima Y; Fukumitsu N; Saito T; Numajiri H; Murofushi KN; Ohnishi K; Nonaka T; Ishikawa H; Okumura T; Sakurai H
    Radiother Oncol; 2019 Jul; 136():37-43. PubMed ID: 31015127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postoperative carcinoembryonic antigen as a complementary tumor marker of carbohydrate antigen 19-9 in pancreatic ductal adenocarcinoma.
    Kim J; Lee YS; Hwang IK; Kang BK; Cho JY; Yoon YS; Han HS; Hwang JH
    J Korean Med Sci; 2015 Mar; 30(3):259-63. PubMed ID: 25729247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the prognostic impact of pre- and post-operative CA19-9, SPan-1, and DUPAN-II levels in patients with pancreatic carcinoma.
    Kondo N; Murakami Y; Uemura K; Nakagawa N; Takahashi S; Ohge H; Sueda T
    Pancreatology; 2017; 17(1):95-102. PubMed ID: 27746094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer.
    Kinsella TJ; Seo Y; Willis J; Stellato TA; Siegel CT; Harpp D; Willson JK; Gibbons J; Sanabria JR; Hardacre JM; Schulak JP
    Am J Clin Oncol; 2008 Oct; 31(5):446-53. PubMed ID: 18838880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of SUVmax and serum carbohydrate antigen 19-9 in pancreatic cancer.
    Zhao JG; Hu Y; Liao Q; Niu ZY; Zhao YP
    World J Gastroenterol; 2014 May; 20(19):5875-80. PubMed ID: 24914348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of tumor volume and its change on survival in stage III non-small cell lung cancer treated with definitive concurrent chemoradiotherapy.
    Koo TR; Moon SH; Lim YJ; Kim JY; Kim Y; Kim TH; Cho KH; Han JY; Lee YJ; Yun T; Kim HT; Lee JS
    Radiat Oncol; 2014 Dec; 9():283. PubMed ID: 25498887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative CA 19-9 level is an important prognostic factor in patients with pancreatic adenocarcinoma treated with surgical resection and adjuvant concurrent chemoradiotherapy.
    Hallemeier CL; Botros M; Corsini MM; Haddock MG; Gunderson LL; Miller RC
    Am J Clin Oncol; 2011 Dec; 34(6):567-72. PubMed ID: 21150564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can preoperative and postoperative CA19-9 levels predict survival and early recurrence in patients with resectable hilar cholangiocarcinoma?
    Wang JK; Hu HJ; Shrestha A; Ma WJ; Yang Q; Liu F; Cheng NS; Li FY
    Oncotarget; 2017 Jul; 8(28):45335-45344. PubMed ID: 28484084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
    Distler M; Pilarsky E; Kersting S; Grützmann R
    Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.